Selux Diagnostics is developing a Next Generation Phenotyping (NGP) platform that promises to transform infectious disease patient treatment by dramatically increasing the speed and accuracy with which targeted, personalized antibiotic therapies can be prescribed. Earlier, better-informed treatment decisions will save lives, improve patient outcomes, decrease hospital lengths of stay and hospital acquired infections, and help combat the global antibiotic resistance epidemic. The CDC has cited bacterial resistance to antibiotics among the world's deadliest and costliest health threats. Using current technologies, doctors must overprescribe powerful, broad-spectrum antibiotics for days while waiting for key diagnostic results to direct personalized therapy. SeLux NGP is the only platform capable of delivering personalized therapy results for all patients within a day of hospital entry, speeding this targeted treatment by an average of 2 days and as many as 4 days for patients infected with multi-drug resistant organisms. Selux Diagnostics was founded in 2014 by two Yale- and Harvard-trained engineers working in an improvised attic laboratory. On September 25, 2018, SeLux announced that it had signed a milestone-based contract worth up to $45 million with BARDA, a division of the U.S. Department of Health and Human Services' (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR). SeLux immediately receives $9.3 million from BARDA to fund the clinical trial necessary for SeLux NGP, SeLux's next-generation phenotyping platform. The additional $36 million will fund the development of SeLux's second-generation rapid sepsis diagnostic system. SeLux has also raised $25 million in Series B financing to support the pivotal FDA trial for SeLux's NGP platform. The round was led by Sands Capital Ventures and included returning investors RA Capital and Schooner Capital and new investors Sands Capital and Northpond Ventures.